We provide services for innovative and disruptive companies in healthcare

Stonegate Healthcare (SH) provides guidance to public and private healthcare companies to accelerate meaningful innovations in healthcare through strategy, thematic research, business development, and investor outreach.

SH assists business development teams in partnering/acquiring/selling assets through a combination of our network of corporations, investors, universities, etc., technology, and process all tailored to address the goals of each client.

SH research focuses on thematic pieces that provide insight into emerging and disruptive technologies in areas of medicine that can have a meaningful impact on the future of healthcare.

SH has expertise building and managing investor/strategic relationships with a focus on helping our clients achieve market valuations and access to sources of growth capital.

SH helps companies develop messaging that captures the attention the of their target audience and conveys their mission; messaging is a critical component of business development, investor relations, or crisis management. SH also helps our clients build a quarterly and annual communications strategy, as well as train management to better communicate their message efficiently.

Our affiliate, Stonegate Capital Markets (Member FINRA/SIPC), provides company-specific research services and investment banking services for public and private companies.

Shiv S. Kapoor

Shiv S. Kapoor
Co-Founder
Stonegate Healthcare


Shiv is a Co-Founder of Stonegate Healthcare and is a biotech veteran with over 25 years of experience in investments and the development of Oncology therapeutics. He has been rated among the top three biotechnology analysts by Forbes in the US. Shiv ran the Smith Barney Biotech fund at Citigroup and started Sellside Biotech practices at Montgomery & Co. and Morgan Joseph. His opinion on the US Biotechnology sector has been widely quoted in leading US media including CNN, CNBC, Bloomberg, and Barron's Guide. In the past decade, Shiv led investor relations and corporate strategy at Spectrum pharmaceuticals. In 2020 he founded BioRamon Pharmaceuticals, a biopharmaceutical company involved in early discovery and research of oncology medicine. Shiv has a BA in Biochemistry from UC Berkeley and an MBA from the University of Chicago Booth School of Business.

Jesse Shelmire

Jesse Shelmire
Co-Founder
Stonegate Healthcare


Jesse is Co-CEO/Partner of Stonegate Capital Partners/Stonegate Capital Markets(Member FINRA/SIPC), and a Co-Founder of Stonegate Healthcare Partners. Jesse spent the first decade of his investment career in 1981 at Smith Barney in retail sales and then later at Jefferies in institutional sales. In the mid-90’s, Jesse was the Managing Director of Investment Banking for First London Securities where he managed public and private transactions. In 1999, Jesse joined Stonegate where he’s managed ~100 transactions and currently provides advisory services for both public and private companies with a focus on healthcare. Jesse received his Bachelor of Science in Economics in 1979 from The Wharton School of Business at the University of Pennsylvania. Jesse is licensed with Stonegate Capital Markets and currently holds FINRA Series 7,24, 63, 79, 99 licenses.

Alamgir Singh Kandhari

Alamgir Singh Kandhari
Analyst
Stonegate Healthcare


Alamgir is a Research Analyst at Stonegate Healthcare and has a BA in Biology from UC Santa Cruz and a Master of Biotechnology & Stem Cell Science from San Jose State University. At UCSC, Alamgir did research in the Sanford Lab to better understand aberrant pre-mRNA splicing mechanisms causing genetic diseases. At BioMarin Pharmaceuticals, he ran cell culture and protein purification GMP production processes. Prior to his role at Stonegate, Alamgir worked at Notable labs, an immuno-oncology company, to develop the ex-vivo assay platform allowing Notable to target Leukemia Stem Cells in AML. He has experience in scientific writing, presenting, experimental, GMP production, and project management. Concurrently he is leading business development at BioRamon Pharmaceuticals to in license and develop oncology drugs.